In an experimental model of NAFLD, abnormal PINK1/Parkin-dependent mitophagy might be responsible for hepatic FA accumulation and treatments aimed at increasing PINK1/Parkin-mediated mitophagy (as quercetin), accelerated mitochondrial FA oxidation, and suppressed FA accumulation. This evidence concerns the gene PRKN and metabolic dysfunction-associated steatotic liver disease.